Pimoben 1.25/2.5 mg and 5/10 mg tablets contain pimobendan and benazepril hydrochloride as active ingredients as inotrope and ACE (angiotensin-converting enzyme) inhibitor for the management of congestive heart failure. Management of heart failure has markedly changed over the last few years. Drugs that only prove hemodynamics may actually result in long term harm. It is observed that controlling the body’s maladaptive neurohormonal response like (RAAS – Renin angiotensin aldosterone system) is of foremost importance in heart failure patients.
Benazepril acts on activated RAAS and reduces angiotensin II and aldosterone which prevents cardiac remodeling and slows down the progression of CHF (congestive heart failure). Reduction in sodium and water retention reduces fluid build-up and protects kidney health. Pimobendan works as a heart stimulant which moderates vasodilation with the strong vasodilation effect of benazepril it reduces heart workload. Pimobendan increases cardiac muscle contraction which increases cardiac output.